

EQA round: RF2/23 - Diagnostics of Rheumatoid Arthritis and ASLO

Deadline: 29.9.2023

Setup: groups - manufacturer of kit; Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	CVPG = consensus of the participants' groups	UL = upper limit
N _{tot} = total number of the results	U _{AV} = expanded uncertainty of the assigned value (k = 2)	N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL				
Set 1															
(231) Rheumat. fac. (scr)	[kU/L]				15							13	7	54	
Sample A1		7,45	3,8	51	15		CVP	8,52	0,9	asym.	0	20	15	11	73
(58) Beckman Coulter (AU)		8	3,1	39	5	1							5		
(60) Roche		9,01	2,4	26	5	1							5		
Other					5	1							5		
							1x 1, 1x 148, 1x 162, 1x 178, 1x 179								
Sample B1		340	100	30	15								13	7	54
(58) Beckman Coulter (AU)		270	210	79	5	1	CVPG	337	64	33%	225	449	5		
(60) Roche		288	190	64	5	1	CVPG	396	6,7	33%	265	527	5		
Other					5	2							3		
							1x 1, 1x 148, 1x 162, 1x 178, 1x 179								
Set 2															
(237) anti-streptolysin O (ASLO)	[kU/L]				21							19	19	100	
Sample A2		135	18	13	21								19	19	100
(58) Beckman Coulter (AU)		138	5,5	4	9	0	CVPG	139	3,1	20%	111	167	9		
(60) Roche		140	22	16	6	0	CVPG	144	3,5	20%	115	173	6		
Other					6	0							4		
							3x 1, 1x 162, 2x 178								
Sample B2		317	43	14	21								19	19	100
(58) Beckman Coulter (AU)		313	17	5,4	9	0	CVPG	319	6,1	20%	255	383	9		
(60) Roche		346	35	10	6	0	CVPG	354	7,7	20%	283	425	6		
Other					6	0							4		
							3x 1, 1x 162, 2x 178								